Reuters logo
8 个月内
BRIEF-Aduro Biotech says U.S. FDA has lifted partial clinical hold placed on its clinical trials evaluating ladd immunotherapy platform
2016年11月21日 / 下午1点07分 / 8 个月内

BRIEF-Aduro Biotech says U.S. FDA has lifted partial clinical hold placed on its clinical trials evaluating ladd immunotherapy platform

1 分钟阅读

Nov 21 (Reuters) - Aduro Biotech Inc :

* Says U.S. Fda has lifted partial clinical hold placed on its clinical trials evaluating ladd (live, attenuated double-deleted) immunotherapy platform

* Says the fDA action enables patient enrollment to resume in all aduro-sponsored clinical studies

* Aduro Biotech says it remains on track to initiate phase 2 clinical study using ladd-based therapy CRS-207 in combination with anti-pd-1 compound in first half of 2017

* Partial clinical hold lifted and enrollment resumes for Aduro Biotech ladd clinical trials Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below